Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811491 | 1.00 | HTR1D (0.34) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL5092368 | 0.85 | HTR1D (0.36) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6808310 | 0.85 | ESR1 (0.36) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL5090741 | 0.84 | SMYD2 (0.38) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6811129 | 0.81 | HTR1D (0.52) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL5093705 | 0.81 | HTR1D (0.52) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL5097946 | 0.81 | HTR1D (0.43) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6812077 | 0.81 | HTR1D (0.43) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6812143 | 0.81 | CA14 (0.42) | HTR1DDRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6811827 | 0.79 | HTR1D (0.42) | HTR1DDRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR1D 201/4885DRD2 207/4885HTR2A 131/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR1D 124/4885DRD2 1606/4885HTR2A 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.